Aptar has signed a multi-year enterprise agreement with Biogen to develop digital health solutions aimed at enhancing care for patients with neurological and rare diseases.
The partnership leverages Aptar’s capabilities to support the development and operation of new and existing digital health solutions worldwide.
Under the agreement, Biogen will transfer ownership of select solutions to Aptar, which will provide a comprehensive range of services.
The services include product management, design, development, software application maintenance, secured cloud hosting, and customer and marketing support.
Aptar Digital Health president Pierre Leurent said: “We are excited to leverage our end-to-end capabilities to support Biogen and enable patients and their care teams to benefit from advanced digital solutions for better disease management.
“With this new agreement, Aptar Digital Health’s activities are significantly expanding in neurology and immunology, two strategic therapeutic areas. We look forward to an exciting collaboration between both our groups in the coming years.”
The initial scope of the agreement covers several indications in immunology and neurology in 15 countries.
The first solutions to transition to Aptar's operation in North America, Europe/UK, Asia-Pacific, and Latin America are Cleo/Aby and Physio.me.
Cleo/Aby is a digital care companion app designed to assist individuals living with multiple sclerosis by providing disease information, symptom tracking, reminders related to treatment, and tailored self-care programmes.
Physio.me is a digital exercise companion offering at-home, customised exercises for patients with neuromuscular disorders, allowing them to measure and share progress with their care teams.
Furthermore, the collaboration may lead to the development and market introduction of new digital health solutions for managing conditions such as spinal muscular amyotrophy, Friedreich’s ataxia, and lupus in selected countries.
Last year, Biogen signed a licence and collaboration agreement with Alcyone Therapeutics for the development of an implantable medical device for intrathecal drug delivery.
